Match Document Document Title
8404231 Lysyl oxidase-like 1 (LOXL1) and elastogenesis  
Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions,...
8389474 Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion  
Ischemia-reperfusion (IR) injury involving harvested organs and allograft transplantation may be increased by stimulation of a newly described innate pro-inflammatory immune system...
8389475 Relaxin analogs  
Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.
8377881 Compositions and methods for reducing scar formation in wound healing  
The invention pertains to a method of reducing scar formation during wound healing by administering a phosphatidylserine-binding compound, in particular an annexin, to a subject in need thereof....
8377882 Stabilization of interleukin 6 in serum based solutions  
Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or...
8372808 Suppression of glial fibrillary acidic protein  
Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell....
8372809 Method of treating dyspnea associated with acute heart failure  
The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure...
8367609 Methods of reducing skin damage and edema  
This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of...
8367605 Copolymer-1 improvements in compositions of copolymers  
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
8349799 Pharmaceutical composition of nanoparticles  
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles...
8343919 Cancer treatment using natriuretic peptides  
The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the...
8329657 Fn14/TRAIL fusion proteins and method of treating cancer  
Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as...
8329643 PIMAP39 modulates LPS-induced inflammatory response  
The present invention relates to a novel peptide sequence named PIMAP39 (herein referred to as SEQ ID NO.: 1) and methods of use of the novel sequence and functional variants thereof. The present...
8324161 Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus  
Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus. Leukotriene B4 polypeptide, the polynucleotide encoding Leukotriene B4 polypeptide, and Leukotriene B4 polypeptide related...
8324162 Diuretic and natriuretic polypeptides lacking the blood pressure lowering property  
This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided...
8309088 Method of treating osteoarthritis with an antibody to NGF  
Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or...
8299028 Chimeric peptide antagonist for GPCR135 or GPCR142  
The chimeric polypeptide R3(BΔ23-27)R/I5 is described, which is a high-affinity antagonist for GPCR1 35 and GPCR1 42 over LGR7.
8293711 Use of natriuretic peptides for treating angioedema syndromes  
The present invention relates to the use of a natriuretic peptide, urodilatin, for treating patients suffering from acute drug induced angioedema, such as ACE inhibitor related adverse events....
8288350 Methods to prevent and treat diseases  
Methods and compositions that can treat a variety of tissue injuries and infections are provided. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue...
8288351 Antagonists of the bradykinin B1 receptor  
The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These...
8283318 Aquaretic and natriuretic polypeptides lacking vasodilatory activity  
This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide...
8283317 Nanoparticles for protein drug delivery  
The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively...
8278280 Antagonists of the bradykinin B1 receptor  
The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG....
8263555 Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma  
The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient...
8241640 Pharmaceutical botulinum toxin compositions  
Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target...
8242074 Modulation of the amount or function of pathogenic CD14+CD16+ monocytes  
The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost...
8222211 Methods of administering PIF agonist peptides and uses thereof  
A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but...
8211858 Modified plasminogen activator inhibitor type-1 molecule and methods based thereon  
The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI-1, but is deficient in...
8202835 Disease treatment via antimicrobial peptides or their inhibitors  
The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog...
8198242 Variants of C-type natriuretic peptide  
The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful...
8198241 Use of an agent that restores tissue perfusion and oxygenation  
The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders...
8188058 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders  
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic...
8187672 Residual solvent extraction method and microparticles produced thereby  
Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the...
8188053 Anti-inflammatory peptides  
The present invention relates, inter alia, to a method of ameliorating an inflammatory skin condition. Thus, the present invention provides a peptide that includes the amino acid sequence KMIKP...
8188042 Nanoparticles for protein drug delivery  
The invention discloses bioactive nanoparticles composed of chitosan, poly-glutamic acid, and diethylenetriaminepentaacetic acid for use in radionuclide decorporation during radiological...
8173595 Methods and compositions for the inhibition of thrombus formation  
The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes...
8173596 Prouroguanylin, and synthetic analogs or proteolytic cleavage products derived from it, as therapeutic and diagnostic agents for diseases involving salt and/or fluid homeostasis  
A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized...
8173121 Lysyl oxidase-like 1 (LOXL1) and elastogenesis  
Described are methods of treating and preventing conditions associated with a loss of elastic fibers. Also provided herein are methods of screening for agents useful in treating such conditions,...
8168176 CBLB for treating endotoxin-mediated disorders  
Methods of treating endotoxin-mediated disorders are provided.
8163278 Methods for treating pervasive development disorders  
A method of determining the efficacy of secretin, neuropeptides, peptides, and/or digestive enzymes for treatment of an individual diagnosed with a pervasive development disorder, such as autism,...
8163696 Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues  
GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as...
8153583 Toll like receptor 3 antagonists, methods and uses  
Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.
8138141 HMG1 antibody for treating inflammatory conditions  
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount...
8138150 Method for removing endotoxin from proteins  
Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine...
8133975 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Coagulation factor VII polypeptides
 
The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the...
8114394 Use of IL-1 antagonists to treat gout  
Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to...
8114831 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis  
A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide...
8114437 Solvent/polymer solutions as suspension vehicles  
A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to...
8110549 Alpha-conotoxin peptides  
The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or...
8105584 Method for treating pervasive development disorders  
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and...